Main menu
Click categories to expand
A-Z listingplugin-autotooltip__plain plugin-autotooltip_bigA-Z listing
This is an alphabetical index of all content pages.
Other categories
Utilities
Also see
Importance Ratings
News
Legal
Donate/Sponsor
Curator's rationale
AI Policy
Twitter feed ð•
Feeds + s.e.o. etc.
rss / xml feed 
sitemap file
A-Z listing (archived)
Lacosamide - sold under the brand name Vimpat and others - was discovered at the University of Houston in 1996. It was licenced in Europe and the US in 2008 for the treatment of partial-onset seizures in Epilepsyplugin-autotooltip__plain plugin-autotooltip_bigEpilepsy
"Epilepsy is a chronic noncommunicable disease of the brain that affects around 50 million people worldwide. It is characterized by recurrent seizures, which are brief episodes of involuntary movement that may involve a part of the body (partial) or the entir….
Its precise mechanism of action was unknown at the time of approval, and the exact amino acid targets involved remain uncertain to this day.“
Source Wikipedia
The drug has also been used (with varying degrees of success) to treat : bipolar disorder, cocaine addiction, dementia, depression, diabetic peripheral neuropathy, fibromyalgia, headache, hiccups, Huntington's disease, mania, migraine, obsessive-compulsive disorder, panic disorder, restless leg syndrome, and tinnitus.
In no case has the drug's mechanism of action been fully explained.
Ideas for new topics, and suggested additions / corrections for older ones, are always welcome.
If you have skills or interests in a particular field, and have suggestions for Wikenigma, get in touch !
Or, if you'd like to become a regular contributor . . . request a login password. Registered users can edit the entire content of the site, and also create new pages.
( The 'Notes for contributors' section in the main menu has further information and guidelines etc.)
You are currently viewing an auto-translated version of Wikenigma
Please be aware that no automatic translation engines are 100% accurate, and so the auto-translated content will very probably feature errors and omissions.
Nevertheless, Wikenigma hopes that the translated content will help to attract a wider global audience.
DOKUWIKI IMPLEMENTATION DESIGN BY UNIV.ORG.UK DECEMBER 2023